Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

IPSS-m outperforms IPSS-R in younger adults with Myelodysplastic Syndromes: A retrospective age-stratified analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJin-Jun YangYZYa ZhangYWYu Wu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows IPSS-M enhances risk stratification in younger MDS patients, indicating improved survival prediction.

Key Points

  • IPSS-M offers improved prognostic accuracy in younger adults with myelodysplastic syndromes, distinguishing high-risk disease effectively.
  • Overall survival among younger patients stratified by IPSS-M was markedly different, with a median OS of 14.9 months for extremely high-risk individuals.
  • Next-generation sequencing identified fewer mutations in DAT genes for younger adults, emphasizing their unique biological profile in MDS.
  • Clinical decisions for younger patients can be guided by IPSS-M to enable more personalized management of their condition.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6achttps://doi.org/10.1182/blood-2025-7391
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)2025
  2. 2Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes2025
  3. 3Comparative Analysis of IPSS, IPSS-R, and WPSS for Predicting Survival and Leukemic Transformation in Myelodysplastic Neoplasms: A Real-World Single-Center Experience.2025
  4. 4Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)2025
  5. 5Comparative evaluation of ipss-m and cpss-mol in CMML: Impact of molecular markers on prognosis2025